HCV Protease Inhibitors in Clinical Practice

HCV Protease Inhibitors in Clinical Practice

Currently Approved HCV Agents: Telaprevir and

Boceprevir

Patient Selection for HCV Triple Therapy

Telaprevir: Recommended Treatment Duration (Weeks)

Telaprevir + PEG-IFN-α-2a + RBV for HCV Genotype 1

Boceprevir: Recommended Treatment Duration (Weeks)

Boceprevir + PEG-IFN-α-2b + RBV for HCV Genotype 1

Select Predictors of SVR in Chronic HCV Genotype 1 Therapy

Selected Adverse Events

HCV Treatment-related Anemia

Preparing Patients for HCV Treatment

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)